Interactions of stroke, nonsteroidal anti-inflammatory drugs, and APOE status in dementia risk

Neurology

Volumn 70, Issue 1, 2008, Pages 5-6

  Rogers, Joseph ^a   Sabbagh, Marwan N ^a  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ALZHEIMER DISEASE; CONTROL GROUP; DEMENTIA; DRUG EFFECT; DRUG MECHANISM; EDITORIAL; HAZARD RATIO; HUMAN; NEUROPROTECTION; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; STATISTICAL SIGNIFICANCE; STROKE; STROKE PATIENT;

EID: 37849042911     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000295507.90442.f4     Document Type: Editorial

References (11)

1. Szekely CA, Breitner JCS, Fitzpatrick AL, et al. NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type. Neurology 2008;70:17-24.
2. Jin YP, Østbye T, Feightner JW, Di Legge S, Hachinski V. Joint effect of stroke and APOE 4 on dementia risk: the Canadian Study of Health and Aging. Neurology 2008;70:9-16.
3. Tatemichi CK, Desmond DW, Mayeux R, et al. Dementia after stroke: baseline frequency, risks, and clinical features in a hospitalized cohort. Neurology 1992;42:1185-1193.
4. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 1996;47:425-432.
5. Hayden KM, Zandi PP, Khachaturian AS, et al. Does NSAID use modify cognitive trajectories in the elderly? Neurology 2007;69:275-282.
6. Neuroinflammation Working Group. Inflammation and Alzheimer's disease. Neurobiol Aging 2000;21:383-421.
7. Klegeris A, McGeer PL. Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease. Curr Alzheimer Res 2005;2:355-365.
8. Reines SA, Block GA, Morris JC, et al. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 2004;62:66-71.
9. ADAPT Research Group. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 2007;68:1800-1808.
10. Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001;414:212-216.
11. Szeklo M, Javier Nieto F. Defining and assessing heterogeneity of effects: interaction. In: Szeklo M, Javier Nieto F, eds. Epidemiology: Beyond the Basics. Gaithersburg, MD: Aspen Publishers; 2000:177-253.